Company ProfilePremium

Regencell Bioscience Holdings Limited

Company Profile Analysis

Ticker: RGC

ESOMAR 23 Corporate BadgeISO Certifications Badge
Regencell Bioscience Holdings Limited - Company showcase

Year Founded & Workforce

2014

10 Employees

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Regencell Bioscience Holdings Limited Overview

Regencell Bioscience is a pre-revenue Hong Kong company developing Traditional Chinese Medicine (TCM). It is trying to turn a family-held herbal practice into standardized, registrable liquid formulas for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

Its scientific basis is a formula base and the "Sik-Kee Au TCM Brain Theory®". Both were developed over about 30 years by Sik-Kee Au, the CEO's father, who is the company's contractual research partner. Sik-Kee Au trained as an electrical engineer before becoming a TCM practitioner.

The near-term regulatory goal is proprietary Chinese medicine (pCm) registration in Hong Kong. The company has:

  • no approved products;

  • no granted or pending patents;

  • no distribution capability;

  • about ten employees.

In the market, Regencell is better known as one of 2025's most extreme equity anomalies. The shares rose roughly 48,000–60,000% within weeks, and the company's market value at times exceeded USD 30 billion. A U.S. Department of Justice investigation into trading in the shares followed.

For investors, Regencell is effectively a control-concentrated, very thinly floated option on unproven TCM science.


Company's own description (paraphrased from the FY2026 Form 20-F)

Regencell describes itself as an early-stage TCM bioscience company with a limited operating history. It focuses on researching, developing and commercializing TCM to treat neurocognitive disorders and degenerations, specifically ADHD and ASD.

The company's own disclosures state that:

  • it has no saleable products and has not generated any product revenue;

  • it has not applied for any regulatory approval;

  • it holds no granted or pending patent applications;

  • it has no distribution capabilities or experience.

Operations have been funded mainly by the July 2021 IPO and, from May 2026, by a registered direct offering. The company plans to launch three liquid-based standardized TCM formula candidates, for mild, moderate and severe ADHD/ASD, first in Hong Kong and later in other markets. The FY2025 20-F summary also refers to planned distribution through:

  • clinics;

  • proprietary product registration;

  • TCM wholesalers and retail stores;

  • later expansion to the U.S. and other international markets.

Business model and revenue model

DimensionCurrent state (FY2026)Intended future state (per filings)
Revenue mix0% product, 0% service, 0% subscription, 0% licensing. No revenue since inceptionProduct sales of registered pCm liquid formulas. Possibly clinic-based treatment services. Licensing or collaboration revenue is mentioned only as a possibility
Value chain positionUpstream research and development (R&D) only. Raw materials are sourced by the TCM Practitioner from Hong Kong vendorsIntegrated developer and brand owner. Manufacturing is likely outsourced to GMP-compliant third parties. Distribution through own channels or third parties
Customers—Pediatric ADHD/ASD patients and their parents and caregivers, TCM clinics, TCM wholesalers and retail stores
End-marketsNone commercialHong Kong TCM market first. The 20-F refers to more than 6,000 TCM stores, wholesalers and other channels in Hong Kong. Later the U.S. and other international markets
ManufacturingNone. No contract manufacturer engaged (FY2026 20-F)Third-party contract manufacturers
Sales and marketingNone. The company says it does not currently intend to build a sales forceThird-party commercialization partners, at least initially

Independent characterization

Regencell is economically a single-asset, founder-controlled research vehicle. Its intellectual property is a family-derived herbal formula set and a trademarked diagnostic theory. Because it holds no patents, protection rests mainly on:

  • trade secrets;

  • trademarks;

  • partnership agreements with the CEO's father.

Its evidence base consists of small, non-blinded, company-run "efficacy trials". These used parent- and caregiver-reported rating scales plus a proprietary 48-item questionnaire (SKATBT-A3) designed by its own R&D team.

Cash operating spend has typically been USD 3–5 million a year. FY2026's reported loss of USD 11.7 million was inflated by legal fees, professional fees and share-based compensation.

The listed equity has been dominated by trading dynamics rather than fundamentals:

  • free float has been roughly 11–12%;

  • short interest has spiked repeatedly;

  • the company says its price swings since 2025 had no link to any change in its financial condition or results.

The company is also a "controlled company" under Nasdaq rules. U.S. holders face a Passive Foreign Investment Company (PFIC) designation for FY2026.

Strategy

Stated strategy (themes paraphrased from filings and releases)

  1. Save and improve lives of ADHD/ASD patients. The company aims to become a market leader in ADHD/ASD treatment globally, starting from Hong Kong.

  2. Standardize the founder-family formula. It plans to move from personalized prescriptions to three standardized liquid formulas (mild, moderate and severe) suitable for pCm registration.

  3. Registration first, then commercialization. The company plans to complete the second efficacy trial, file for pCm registration with Hong Kong regulators, then outsource manufacturing and use third-party channels.

  4. Hong Kong first, then international. Later expansion to the U.S. and other markets is planned through Regencell Bioscience North America.

Initiatives announced in the last 24 months (October 2024 – October 2026)

DateInitiativeDetailStatus
Jun 202538-for-1 forward splitStated aim: improve liquidity and accessibilityCompleted
Jun 2025Board refreshMargaret Hoor Han Lo appointed independent directorCompleted
Ongoing (FY2025–FY2026)Internal control remediationHiring and outside U.S. GAAP/SEC experts, oversight of non-recurring transactions, consultant-led control assessment, formal policiesIn progress; three material weaknesses remain at FY2026
30 Mar 2026F-3 shelf and USD 500M ATM programCreates very large potential capacity to issue sharesShelf effective; ATM unused at 30 Jun 2026
19–22 May 2026USD 20M registered direct offeringLed by a new "fundamental institutional investor"Closed
FY2026 20-FPossible digital asset treasury policyManagement may consider investing in Bitcoin, Ethereum or crypto exchange-traded products; no purchases madeUnder consideration only
FY2026 20-FAI adoptionCompany may use AI in operations; risk factor addedExploratory
OngoingSecond efficacy trial in Hong KongStandardized formulas; company says it is unsure whether a redesign will be neededOngoing; no completion date disclosed

Sustainability and ESG commitments: none disclosed beyond a generic risk factor.

Cost programs with targets: none disclosed.

Medium-term financial targets and guidance: none. The company gives no revenue, profitability or registration timeline. A 2022 sponsored research note referred to a four-year timeframe to commercialize and obtain pCm registration; that timeframe has passed without a filing.

Products & Services

None of the items below is approved or commercially available. All are development candidates or brand assets.

Trial endpoints used in the efficacy trials (FY2026 20-F):

  • SKATBT-A3 (proprietary);

  • Autism Treatment Evaluation Checklist (ATEC);

  • Gilliam Autism Rating Scale (GARS);

  • Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS);

  • SNAP-IV 26-item Parent Rating Scale.

The company acknowledges these depend on data reported by parents and caregivers, which may be biased.

Product Portfolio

#Product / assetSegmentDescriptionDevelopment statusTarget customerYearPricing
1

Standardized liquid TCM formula: Mild ADHD/ASD

TCM R&D

Orally administered liquid herbal formula derived from the TCM Practitioner's base formula plus a standardized adjustable component. Dosed twice daily for a 3-month course in trials

In the second efficacy trial (non-blinded); trial still ongoing per FY2026 20-F; no regulatory filing

Children and patients with mild ADHD/ASD; parents and caregivers

Candidates defined before the 2021 IPO

—
2

Standardized liquid TCM formula: Moderate ADHD/ASD

TCM R&D

Same platform, calibrated for moderate severity

Same as above

Moderate ADHD/ASD

Before IPO

—
3

Standardized liquid TCM formula: Severe ADHD/ASD

TCM R&D

Same platform, calibrated for severe severity

Same as above

Severe ADHD/ASD

Before IPO

—
4

Personalized TCM formula

TCM R&D

Practitioner-adjusted individual prescriptions; the basis of the first study (2019) and first efficacy trial

Completed; company states its results may not predict outcomes for the standardized formulas

Individual patients

2019—
5

RGC-COV19™ (internal JV code RGCA-CV01)

Infectious disease (historical)

Liquid TCM formula targeting mild-to-moderate COVID-19 symptoms over a 6-day course

EARTH-A (37 patients) and EARTH-B (51 patients) company-run trials in 2021–2022, not peer reviewed. No current development disclosed in the FY2026 20-F, which focuses solely on ADHD/ASD

COVID-19 patients in ASEAN countries, India, Japan, Australia and New Zealand (via the JV)

2020–2022

—
6

SKATBT-A3 (Sik-Kee Au TCM Brain Theory® for ADHD/ASD Assessment)

Assessment tool

48-item questionnaire built by the company's R&D team to capture conditions the Practitioner observes under his brain theory

Used as a trial endpoint

Internal research use

2021–2022

Not applicable

7

Trademark: 腦還原® ("brain restoration")

Brand

Registered with the Hong Kong Registrar of Trade Marks

Registered

Consumer brand

—

Not applicable

8

Trademarks: RGC Regencell® and RGC®

Brand

Corporate and product marks, Hong Kong

Registered

Not applicable

—

Not applicable

9

Trademark: Sik-Kee Au TCM Brain Theory®

Brand / IP

Theory underpinning the formulas (shown with ™ before IPO, ® by 2026)

Registered

Not applicable

—

Not applicable

“—” = not publicly disclosed.

StudyDesignKey reported outcomeSource

First research study (2019)

Personalized formula, 7 pediatric patients, Hong Kong

Assessment scores fell; no controlled data

Renaissance Capital; CEO letter Aug 2021

First efficacy trial

Personalized formula, 3 months

Mean improvement of 30% in ADHD symptoms (VADRS) and 37% in ASD symptoms (ATEC)

Company release via QuantisNow

Second efficacy trial (interim, Sep 2022)

Standardized formulas, non-blinded, 3 months, twice daily

Mean improvement of 37% on SKATBT-A3

Business Wire, 12 Sep 2022

EARTH-A

RGC-COV19™, 1 Oct 2021 – 31 Jan 2022, 37 patients

97.3% complete symptom elimination within 6 days

Company release

EARTH-B

RGC-COV19™, 30 Jan – 31 Mar 2022, 51 patients

94.1% complete symptom elimination within 6 days

Company release

EARTH-A and EARTH-B combined

88 patients

95.5% complete symptom elimination within 6 days; 29.7% tested negative within 6 days

Company release

Financial Detail

Group Entities

EntityJurisdictionOwnershipFunction

Regencell Bioscience Holdings Limited

Cayman Islands

Listed parent

Holding company; Nasdaq issuer

Regencell Bioscience Limited

Hong Kong

100%

Main operating subsidiary: R&D, efficacy trials, partnership with the TCM Practitioner

Regencell Limited

Hong Kong

100%

Hong Kong subsidiary (function not separately described in sources reviewed)

Regencell Bioscience North America Limited

British Virgin Islands

100%

Vehicle for intended North American expansion

Regencell (BVI) Limited

British Virgin Islands

Owned by the CEO (not a subsidiary)

CEO's holding vehicle for his controlling stake

Former COVID-19 JV with Honor Epic Enterprises (company releases referred to a "Regencell Asia" entity)

Not specified

Formerly 60%

Not named among the subsidiaries in the FY2026 20-F definitions. Current status (dissolved, disposed or dormant) is not publicly disclosed in the sources reviewed

Segment Revenue

SegmentFY2024FY2025FY2026

TCM R&D segment revenue (USD Mn)

000

Total revenue (USD Mn)

000

Results by Segment

Segment metricFY2024FY2025FY2026

Segment pre-tax loss (USD Mn)

-4.36-3.58-11.70

Share of total revenue (%)

000

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (USD Mn)

00000

Gross profit (USD Mn)

00000

Research and development (USD Mn)

2.511.581.070.951.30

General and administrative (USD Mn)

5.084.433.552.8110.42

Selling and marketing (USD Mn)

0.030.260.130.010.01

Total operating expenses (USD Mn)

7.626.274.743.7711.72

Operating income (USD Mn)

-7.62-6.27-4.74-3.77-11.72

Interest and other income (USD Mn)

0.020.090.370.190.02

Pre-tax income (USD Mn)

-7.59-6.06-4.36-3.58-11.70

Net income (USD Mn)

-7.59-6.06-4.36-3.58-11.70

Net income attributable to Regencell (USD Mn)

-7.42-5.87-4.30-3.58-11.70

Comprehensive loss (USD Mn)

———-3.60-11.68

Share-based compensation (USD Mn)

—0.920.450.243.20

Depreciation (USD Mn)

—0.290.310.08—

ROU asset amortization (USD Mn)

—0.480.440.32—

EBITDA, derived (USD Mn)

-7.02-5.50-3.99-3.38—

EPS basic, split-adjusted (USD)

-0.02-0.01-0.01-0.01-0.02

EPS diluted, split-adjusted (USD)

-0.02-0.01-0.01-0.01-0.02

Dividends per share (USD)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Net loss growth YoY (%)

462-20-28-18227

Operating expense growth YoY (%)

452-18-24-20211

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (USD Mn)

———5.76—

Cash and equivalents (USD Mn)

————14.19

Total liabilities (USD Mn)

———0.90—

Shareholders' equity (USD Mn)

———4.86—

Goodwill and intangibles (USD Mn)

00000

Shares outstanding (M)

494.49494.49494.49494.49495.88

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (USD Mn)

——-4.00-3.11—

Equity raised, net (USD Mn)

000018.62

Dividends paid (USD Mn)

00000

Share buybacks (USD Mn)

00000

Returns & Leverage Ratios (%)

RatioFY2025Basis

ROE (%)

-74

Net loss / ending equity (USD 3.58M / USD 4.86M)

ROA (%)

-62

Net loss / ending total assets (USD 3.58M / USD 5.76M)

Debt / equity

Approx. 0 (excluding leases)

No borrowings identified

Asset turnover

0

No revenue

Geographic Revenue

RegionFY2024FY2025FY2026

Hong Kong revenue (USD Mn)

000

North America revenue (USD Mn)

000

Rest of world revenue (USD Mn)

000

Total revenue (USD Mn)

000

Share Price

MetricOct2021Oct2022Oct2023Oct2024Oct2025Jul2026

Share price, split-adjusted (USD)

0.350.720.420.1716.655.98

Share Price (Mar2025–Mar2026)

MetricMar2025Apr2025May2025Jun2025Dec2025Mar2026

Month-end price, split-adjusted (USD)

0.841.5823.0817.0421.0025.43

Share Price & Returns

HorizonApprox. returnBasis

1 year

About -60% to -65%

Oct 2025 (16.65) to Sep 2026 (about 5.8). iocharts shows a 12-month CAGR of -57.3%

3 years

About +1,300%

Oct 2023 (0.42) to about 5.8. iocharts shows a 3-year CAGR of 136%

5 years

About +1,550%

Oct 2021 (0.35) to about 5.8. iocharts shows a 5-year CAGR of 36%, which conflicts with this calculation (possibly a different base); discrepancy noted

Since IPO

About +2,200%

IPO at USD 9.50 pre-split (USD 0.25 adjusted)

From all-time high

About -92.6%

Closing high USD 78.00 (17 Jun 2025)

Valuation Multiples

MultipleRegencell

P/E

Not meaningful (loss)

EV/EBITDA

Not meaningful (negative EBITDA)

EV/Sales

Not meaningful (zero sales)

P/B

Several hundred to about 2,300 times (MarketBeat about 684x; iocharts about 2,328x; varies with the equity base and date)

Market cap / cumulative 5-year R&D

About 385 times (USD 2.85B / USD 7.4M)

Capital Markets

ItemStatus

Analyst consensus

No sell-side coverage (Simply Wall St: 0 analysts). Algorithmic "targets" on aggregator sites are not analyst consensus

Dividend history and policy

No dividends ever paid; none expected for the foreseeable future (20-F)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Short interest

Peaked at about 2.26M shares (Aug 2025); 606,522 shares (13 Mar 2026); about 4% of float (MarketBeat)

Trading halts

Multiple volatility trading pauses in 2025–2026

Equity issuance capacity

USD 500M ATM (unused at 30 Jun 2026); remaining F-3 shelf capacity

Analyst Conclusions

Management guidance and consensus

Management guidance: none. The company says it expects operating losses to increase for the foreseeable future as research continues and if commercialization begins.

Consensus: no analyst coverage, so no consensus growth expectations exist.

Bull case

  1. Funded and debt-free for the first time since the IPO. About USD 14.2M of unused proceeds compares with a core cash burn of roughly USD 3–5M a year, excluding legal costs. The USD 500M ATM could fund a properly designed, controlled trial program far beyond anything attempted to date.

  2. Legal overhang easing. The securities class action was voluntarily dismissed on 14 September 2026. If the DOJ investigation ends without charges against the company, governance-driven costs (USD 3.13M of extra professional fees in FY2026) should fall away.

  3. Real unmet need and a culturally receptive home market. There is no approved therapy for core ASD symptoms. Parents in Hong Kong and Asia widely accept TCM. A first registered pediatric ADHD/ASD pCm in Hong Kong would be a differentiated asset, and trademarks such as 腦還原® are already registered.

Bear case

  1. The valuation is unconnected to the asset. About USD 2.85B of market value rests on zero revenue, no patents and cumulative five-year R&D of about USD 7.4M. The company itself says its price moves are unrelated to its fundamentals. The thin float (about 11%) and repeated squeezes make price discovery unreliable.

  2. Science and governance credibility deficits. The trials are non-blinded and rely on parent-reported, partly proprietary endpoints. The IP comes from the CEO's father. Three material weaknesses persist. The auditor changed in FY2026. A DOJ trading investigation remains open as far as public disclosure shows.

  3. Dilution and tax overhang. The May 2026 placement was priced at a 27% discount, and the shares fell about 75% within weeks. The USD 500M ATM is large relative to the float. PFIC status for FY2026 and the 88.3% controlling stake limit the institutional buyer base.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Second efficacy trial completion or redesignFirst standardized-formula evidence since the September 2022 interim readout
Any pCm registration filing with Hong Kong regulatorsWould be the first regulatory step ever taken
DOJ investigation developmentsPossible fines or penalties; management distraction
ATM usage disclosed in 6-K and 20-F filingsPace of dilution
Digital asset treasury decisionCould change the risk profile and PFIC analysis
Material weakness remediationAudit quality and listing risk
First-half FY2027 results (expected around May–June 2027)Burn rate after the legal costs
Changes in insider or free-float structureLiquidity and susceptibility to squeezes
Nasdaq or SEC actions on trading anomaliesListing risk

Analyst verdict

Regencell Bioscience is best analysed as two separate objects that happen to share a ticker.

The first is an operating company. It is a roughly ten-person Hong Kong research outfit trying to standardize and register a family-derived herbal formula for ADHD and autism. Over five years it has spent about USD 7.4 million on R&D and holds no patents. Its evidence is non-blinded and largely reported by parents. It has never applied for regulatory approval or generated a dollar of revenue.

Its economics have been frugal, with operating expenses of USD 3–5 million a year before FY2026. Its balance sheet is now clean and modestly funded after the May 2026 placement. The scientific premise is unproven rather than disproven. A credible path to value would require a properly controlled trial, a pCm filing and a commercialization partner. None of these is yet in view, and the second efficacy trial has run since at least 2022 without a final readout.

The second object is the listed equity. It is an 88%-insider-owned, about 11%-float instrument that has moved from USD 0.09 to USD 78 and back to about USD 6 in eighteen months. These swings are what the company itself calls unrelated to its operations, and they have drawn a DOJ investigation.

Even after a 92% fall from its peak, the market capitalization of about USD 2.85 billion still implies a value several hundred times book. The company can also issue up to USD 500 million of stock through its at-the-market program.

On the evidence in the filings, the equity offers no fundamental margin of safety. It carries asymmetric downside from three sources: dilution, regulatory or legal developments, and a normalization of float dynamics. Upside depends on controlled clinical validation that the company has not yet attempted.

Verdict: a speculative, governance-impaired, pre-clinical-equivalent TCM developer whose equity is not underwritable on fundamentals. For institutional purposes it should be monitored only for:

  • a controlled trial readout;

  • a regulatory filing;

  • resolution of the DOJ matter.


All figures are in USD with a fiscal year ending 30 June unless stated otherwise. Third-party market data (prices, market capitalization, ownership aggregates) is approximate and dated as noted.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge

Yat-Gai Au

Founder, Chairman of the Board and CEO

Since 2014

Studied at UC Berkeley's Haas School of Business; worked at Deutsche Bank in the 1990s; has spoken publicly about having ADHD and dyslexia (Bloomberg via WION)

54 (MarketScreener)

James Wai Hong Chung

Chief Operating Officer and executive director; also styled Chief Scientific Officer in 2021 releases

COO since 1 Aug 2021; director since 28 Dec 2023

Corporate IR contact on 2021 releases

49 (MarketScreener)

Yat-Pui Au

Chief Business Officer

CBO since 1 Feb 2023 (previously senior vice president)

More than 24 years in strategic management and business operations, including physical security and property management; began as a consultant analyst at Computer Sciences Corporation; BA in Legal Studies, UC Berkeley; brother of the CEO

—

Chief Financial Officer

——

The CFO's identity was not confirmed in the sources reviewed. The FY2026 20-F reports material weaknesses, including a shortage of staff with U.S. GAAP and SEC reporting expertise

—

“—” = not publicly disclosed.

Board of Directors

NameRoleSinceIndependenceNotes

Yat-Gai Au

Chairman and CEO

2014

Not independent; controlling shareholder

Chair and CEO roles combined

James Wai Hong Chung

Executive director (COO)

28 Dec 2023

Not independent

Replaced Dr. Yi-Chung Chao; director fee HK$84,000 a year in cash

Dr. William Wing-Yan Lo, JP

Independent non-executive director

13 Dec 2021

Independent

Age 65 (MarketScreener)

Margaret Hoor Han Lo

Independent non-executive director

30 Jun 2025

Independent

Replaced Mr. Niewiadomski, who resigned for personal reasons

Directors' Remuneration

ItemDetailSource

Aggregate executive and director pay, FY2026

Not publicly disclosed in the sources reviewed. Foreign private issuers disclose aggregate figures in Item 6 of the 20-F; no proxy statement (DEF 14A) is filed

—

Share-based compensation, FY2026

About USD 3.2M (G&A share-based compensation up USD 3.02M year on year)

FY2026 20-F; Panabee

First-half FY2026 share-based compensation (G&A)

USD 1.63M, against 0.22M in the first half of FY2025

First-half FY2026 release

Director fee: James Chung

HK$84,000 a year

6-K, Jan 2024

Bonuses

FY2026 R&D payroll up about USD 0.42M and G&A payroll up USD 1.47M, attributed to bonuses and annual salary adjustments

FY2026 20-F

Major Shareholders

HolderStakeSource / date

Yat-Gai Au (via Regencell (BVI) Limited and spouse)

88.3%

FY2026 20-F

Insiders (aggregate, as reported by MarketBeat)

2.00%

MarketBeat. Conflicts with the 20-F; MarketBeat appears to exclude the BVI holding

Free float

About 11.2%

MarketScreener

Institutions (aggregate)

About 0.13%

MarketBeat

Named 13F holders (small)

Vident Advisory LLC: 29,934 shares. Bank of America Corp: 17,172 shares. Seven Fleet Capital Management: new stake of about USD 92k (Q4 2025). Greenfield Savings Bank

MarketBeat 13F digest, 2026

New institutional investor (May 2026 registered direct offering)

About 936,000 shares (USD 19M / USD 20.30); investor not named

6-K, 19 May 2026

Univest Securities (May 2026 registered direct offering)

About 49,000 shares (USD 1M)

424B5

Samuel Chen (early Zoom investor)

Described as a major backer in 2022; current stake not disclosed

Zacks SCR, 2022

Competitive Landscape

Key Competitors

#CompetitorSegment overlapKey products / positionRevenue (latest FY, approx.)
1

Takeda Pharmaceutical

ADHD stimulants

Vyvanse/Elvanse (lisdexamfetamine), Mydayis; global ADHD leader (Vyvanse now generic in the U.S.)

—
2

Johnson & Johnson

ADHD stimulants

Concerta (methylphenidate extended release)

—
3

Novartis

ADHD stimulants

Ritalin, Focalin (methylphenidate franchise)

—
4

Supernus Pharmaceuticals

ADHD non-stimulant

Qelbree (viloxazine)

—
5

Cingulate Inc.

ADHD (development)

CTx-1301 (dexmethylphenidate)

Pre-revenue

6

Axsome Therapeutics

ADHD (development)

Solriamfetol in ADHD trials

—
7

Beijing Tong Ren Tang group (incl. Tong Ren Tang Chinese Medicine, HKEX: 3613)

TCM manufacturing and retail, Hong Kong and China

Heritage TCM brand with Hong Kong retail network

—
8

China Traditional Chinese Medicine Holdings (HKEX: 0570)

TCM granules and pCm

Concentrated TCM granules

—
9

PuraPharm (HKEX: 1498)

Hong Kong TCM granules

Nong's® concentrated Chinese medicine granules

—
10

Eu Yan Sang (private)

TCM retail, Asia

TCM retail chain

—
11

Behavioral and educational therapy providers

ASD (no approved drug treats core ASD symptoms)

Applied behavior analysis (ABA), speech and occupational therapy

Fragmented

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricRegencell (FY2026)Supernus (2024)Takeda (FY2024)Novartis (2024)

Revenue

USD 0

About USD 0.66B

About JPY 4.58T

About USD 50.3B

Operating margin

Not meaningful (operating loss USD 11.72M)

———

R&D intensity

Not meaningful (R&D USD 1.30M)

———

Approved products

0

Multiple CNS drugs

Large portfolio

Large portfolio

Company Snapshot

10

Employees

$2,840M

Market Cap

2014

Founded

Causeway Bay, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Net cash and no borrowings after the May 2026 raise: USD 14.19M of unused offering proceeds at 30 Jun 2026; USD 18.62M net from the registered direct offering (FY2026 20-F)
  • Access to capital markets despite having no revenue: Automatically effective F-3 shelf (well-known seasoned issuer status) and a USD 500M ATM signed 30 Mar 2026
  • Stable, aligned controlling ownership: CEO owns 88.3%; bought more than USD 5M of shares on the open market after the IPO (2021–2022 releases)
  • Low historical cash burn: Operating cash flow of -USD 3.11M in FY2025; operating expenses of USD 3.77M in FY2025
  • Registered Hong Kong brand assets: Four registered trademarks, including 腦還原® and RGC® (FY2026 20-F)
  • Accessible, non-endangered raw material supply: Ingredients available across more than 6,000 Hong Kong TCM outlets (FY2026 20-F)

Weaknesses

  • No revenue, ever: Zero revenue FY2020–FY2026
  • No patent protection: No patents granted or pending (FY2026 20-F)
  • Weak evidence base: Non-blinded second trial; endpoints include a proprietary 48-item questionnaire; data reported by parents and caregivers (20-F; Sep 2022 release)
  • Key-person and related-party dependence: Wholly dependent on Sik-Kee Au (the CEO's father); no key-man insurance
  • Internal control deficiencies: Three material weaknesses at FY2024, FY2025 and FY2026; no internal audit function
  • Going-concern history: FY2025 auditor (Marcum) issued a going-concern explanatory paragraph
  • Tiny organization: About 10–12 employees

Opportunities

  • Large unmet need in ASD: No approved therapy for core ASD symptoms; U.S. CDC prevalence about 1 in 31
  • First-mover pCm registration for pediatric ADHD/ASD in Hong Kong: Company plans the pCm route; no product registered yet
  • Funding capacity could allow a properly controlled trial: USD 500M ATM capacity, unused
  • Partnering or licensing: 20-F lists collaborations as an option for commercialization and manufacturing
  • U.S. expansion vehicle already in place: Regencell Bioscience North America Limited (BVI)
  • Legal overhang easing: Class action voluntarily dismissed 14 Sep 2026

Threats

  • Federal investigation: DOJ subpoena on trading in the shares, disclosed 31 Oct 2025; possible fines above insurance coverage
  • Massive dilution potential: USD 500M ATM against a USD 2.8–3.0B market cap
  • Valuation collapse risk: Shares down about 92.6% from their all-time high (iocharts, Sep 2026); 2026 range of USD 69.00 to 4.51
  • PFIC status deters U.S. investors: Company believes it was a PFIC for FY2026 (20-F)
  • Scrutiny of China/Hong Kong issuers: 20-F risk factor on scrutiny of U.S.-listed Chinese companies; auditor change in FY2026
  • Entrenched competition: Generic stimulants and multinational ADHD franchises (Takeda, J&J, Novartis)
  • Rising non-scientific costs: FY2026 professional fees up USD 3.13M

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar – Apr 2025Shares start rising from below USD 0.30 (split-adjusted)Start of the speculative episode later alleged as the class period run-up
1 May 2025Shares close at USD 2.03 without company newsPrice move unrelated to fundamentals (class action complaint)
May 2025Shares (split-adjusted) rise above USD 20; pre-split price above USD 800Market value reaches tens of billions
2 Jun 202538-for-1 split announcedAim stated as liquidity; shares nearly quadrupled around the split
13 Jun 2025Split effected (481,476,042 bonus shares)Shares outstanding rise to 494.5M
16 Jun 2025Intraday trading range USD 26.20–83.60; split-adjusted trading beginsExtreme volatility; trading halts
17 Jun 2025Closing high of USD 78.00 (about 48,650% above the class-period start)Peak valuation above USD 30B; CEO among the world's 100 richest on paper (Bloomberg)
20 Jun 2025Shares fall about 27% pre-market; down to about USD 20 within a week of the peakSharp reversal
30 Jun 2025Independent director Niewiadomski resigns; Margaret Hoor Han Lo appointedBoard change at the height of the volatility
30 Jun 2025Short interest jumps to about 1.23M shares, from 27,650Squeeze dynamics
Jul – Sep 2025Shares trade around USD 13–16Consolidation
31 Oct 2025FY2025 20-F filed: net loss USD 3.58M, going-concern doubt, three material weaknessesFundamental red flags confirmed
31 Oct 2025DOJ subpoena and investigation into trading in the shares disclosedMaterial regulatory event
3 Nov 2025Shares fall 18.56% to USD 13.56Later cited as the corrective disclosure
Dec 2025 – Jan 2026Shares recover to USD 21–25Renewed speculation
Jan 2026WSJ (Jonathan Weil) highlights the surge despite a struggling business and the DOJ probeValuation ranks in the top 21 of 261 Nasdaq Biotechnology Index constituents
Jan – Apr 20262026 trading range reaches a high of USD 69.00; volatility halts; daily moves of ±10–50%Continued anomaly
30 Mar 2026F-3 shelf (automatically effective) and USD 500M ATMLarge dilution capacity
24 Apr 2026Securities class action filed in the District of MarylandLitigation risk
27 Apr – 23 Jun 2026Wave of plaintiff law-firm notices (Rosen, Faruqi, Levi & Korsinsky, Bragar Eagel, Portnoy, Robbins, Gross, Bronstein Gewirtz)Reputational overhang
8 May 2026First-half FY2026 results: operating expenses up 170%; total assets USD 3.01MLiquidity strain before the raise
19 May 2026USD 20M registered direct offering priced at USD 20.30, a 27% discountFirst capital raise since the IPO
22 May 2026Offering closes; net about USD 18.62MRunway extended
Jun 2026Shares fall from about USD 24 to about USD 6; trading down more than 14% on several daysValuation reset of roughly 75%
23 Jun 2026Lead-plaintiff deadline passesLitigation milestone
26 Jun 2026Shares at USD 6.48–6.63; brief squeeze day of about +35% on volume of 2.18M sharesVolatility continues at a lower level
22 Jul 2026Shares trade as low as USD 5.692026 low area (company-reported 2026 low: USD 4.51)
18 Sep 2026Shares at USD 5.79; market cap about USD 2.84BLatest verified price point
14 Sep 2026Lead plaintiff voluntarily dismisses the class action; case closedRemoves an important legal overhang
7 Oct 2026FY2026 20-F audit report (HTL International): net loss USD 11.70M; PFIC for FY2026; three material weaknesses persistLatest annual disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Results by Segment: Segment pre-tax loss fell from USD -4.4 Mn in FY2024 to USD -11.7 Mn in FY2026.
Regencell Bioscience Holdings Limited — Results by Segment
Series (USD Mn)FY2024FY2025FY2026
Segment pre-tax loss-4.4-3.6-11.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.